This study evaluates the feasibility of administering meclofenamic acid or pentosan polysulfate sodium as an adjunctive treatment to patients diagnosed with a psychotic disorder. Half of participants will receive meclofenamic acid, while the other half will receive polysulfate sodium.

Chronic, low-grade brain inflammation is involved in the development of schizophrenia and other psychotic disorders. Medications with anti-inflammatory properties, like meclofenamic acid and pentosan polysulfate may help to reduce brain inflammation and serve as a treatment of psychotic disorders.

Inclusion Criteria:

• Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, delusional disorder, other specified schizophrenia spectrum and other psychotic disorders, unspecified schizophrenia spectrum and other psychotic disorders
• Negative pregnancy test in females of childbearing age

Exclusion Criteria:

• Urine drug screen positive for psychostimulants such as cocaine, amphetamines and ecstasy
• Any infection, neoplasm, autoimmune disease or other primary inflammatory condition (3) Previous diagnosis of intellectual disability or dementia
• Current treatment with heparin
• Use of or allergy to non-steroidal anti-inflammatory agent or pentosan polysulfate sodium
• Current or anticipated corticosteroid use
• History of peptic ulcer disease, gastro esophageal reflux disease, or gastrointestinal bleeding
• Those on warfarin or any anticoagulant
• Current treatment with lithium or asthma medication
• Individuals with pre-existing liver, cardiac, or kidney disease